What are your top takeaways in Gyn Cancers from ESMO 2025?

Studies presented at ESMO 2025 give a glimmer of hope to patients with platinum-resistant ovarian cancer, an area of gynecologic oncology where too little progress has been made. There were also numerous trials (too many to discuss here) presented involving ADCs, along with important updates to previously presented/published clinical trials.

Ovarian Cancer Studies: Platinum-Resistant

1. Pembrolizumab vs Placebo Plus Weekly Paclitaxel +/- Bevacizumab for Platinum-Resistant Recurrent Ovarian Cancer:...